Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera’s Chief Medical Officer. In this role, Dr. Salzman will lead efforts to advance Kalytera’s drug candidates into human clinical studies.
“We are thrilled to welcome Dr. Salzman to the Kalytera team,” said Robert Farrell, Kalytera’s President and Chief Financial Officer. “Dr. Salzman brings exceptional clinical research and development expertise and maintains strong ties to our partners in Israel. His leadership experience in both industry and clinical settings will be invaluable as we advance our development programs.”
Dr. Salzman is a renowned physician, inventor, and biomedical entrepreneur who has brought numerous medicines from conception to clinical trials. As the founder of Inotek Pharmaceuticals (Nasdaq: ITEK), a clinical-stage developer of therapies for glaucoma and other serious eye diseases, Dr. Salzman helped raise $92M in venture capital and concluded a $600M licensing transaction with Genentech. Dr. Salzman is also the founder of Orphan Technologies, where he participated in the development of three novel enzyme replacement therapies for rare metabolic diseases.
Dr. Andrew Salzman, M.D.
Dr. Salzman received an undergraduate degree from Yale College, a degree in medicine from Harvard Medical School, and completed a pediatric internship and residency at Columbia University Medical Center. He completed post-doctoral fellowships in pediatric infectious disease, neonatology, pediatric critical care, and mucosal immunology at the Weizmann Institute of Science in Rehovot, Israel, Boston Children’s Hospital Medical Center, and Massachusetts General Hospital. Dr. Salzman has received $102 million in federal grant funding, has authored 175 peer-reviewed scientific publications, and holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
“I am exceedingly impressed with the progress that Kalytera has made in advancing its development programs, which have the potential to serve critically important unmet needs in the field of bone health,” said Dr. Salzman. “I look forward to driving the clinical development strategy, rallying the support of key physician thought leaders, and working with Kalytera’s leadership to bring its novel drug candidates to patients.”
About Andrew L. Salzman, M.D.
Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur. Dr. Salzman founded and built Inotek Pharmaceuticals, a 140-person biotech company that raised $92M in venture capital and concluded a $600M license with Genentech. As CEO of Inotek, Dr. Salzman brought numerous new chemical entities from conception to clinical stage testing, including a treatment for glaucoma that demonstrated clinical proof of concept in late Phase 2 clinical trials. In his role as founder and former Chairman of Orphan Technologies, Dr. Salzman developed three novel enzyme replacement therapies for rare metabolic diseases.
Dr. Salzman has been funded by the U.S. National Institutes of Health (“NIH”), authoring 75 federal grants and receiving $102 million in federal grant funding. In addition to 175 peer-reviewed scientific publications, Dr. Salzman holds 40 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
Dr. Salzman attended Harvard Medical School and completed a pediatric internship and residency at Columbia University. He completed post-doctoral fellowship training in pediatric infectious disease, neonatology, pediatric critical care, and mucosal immunology at the Weizmann Institute of Science in Rehovot, Israel, Boston Children’s Hospital Medical Center, and Massachusetts General Hospital.
Dr. Salzman serves as Founder and Chairman of Radikal Therapeutics, Salzman Capital Ventures, Salzman Lovelace Investments, Tisbury Pharmaceuticals, and Respirometics, and is the Director of Drug Development at Lovelace Respiratory Research Institute.
Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that we believe will address large unmet market needs. Kalytera seeks to commercialize its cannabinoid therapies across a range of disease states, with an initial focus on bone health.
This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market, and the availability of funding sources for continued development of such products. Forward-looking statements are based on management’s estimates, assumptions, and projections, and are subject to uncertainties, many of which are beyond the control of Kalytera. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that potential products that appear promising to Kalytera cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, Kalytera will not obtain appropriate or necessary governmental approvals to market these or other potential products, Kalytera may not be able to obtain anticipated funding for its development projects or other needed funding, and Kalytera may not be able to secure or enforce adequate legal protection, including patent protection, for its products. All forward-looking statements included in this press release are made only as of the date of this press release, and Kalytera does not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.